KY216-tubulin complex captures VASH2 to inhibit NSCLC metastasis

Area of Science:

• Oncology
• Molecular Biology
• Structural Biology

Background:

• Metastasis in non-small cell lung cancer (NSCLC) is a major cause of patient mortality.
• Microtubule-targeting agents (MTAs) show anti-metastatic potential, but their precise mechanisms are not fully understood.

Purpose of the Study:

• To elucidate the anti-metastatic mechanism of the MTA KY216 in NSCLC.
• To investigate the interaction between KY216, αβ-tubulin, and vasohibin-2 (VASH2) in the context of NSCLC metastasis.

Main Methods:

• Crystal structure analysis of KY216 in complex with αβ-tubulin.
• Assessment of KY216's effects on VASH2 levels, epithelial-mesenchymal transition (EMT), and related molecular signaling pathways in NSCLC cells.
• Investigation of the role of miR-429 in the KY216-mediated inhibition of metastasis.

Main Results:

• KY216 binds to curved αβ-tubulin, reducing VASH2 levels and inhibiting EMT in NSCLC.
• KY216 enhances VASH2 binding to α-tubulin, prevents VASH2-mediated ZEB1 activation, and promotes α-tubulin detyrosination, suppressing EMT.
• KY216 upregulates miR-429, which targets VASH2 and ZEB1 transcripts, thereby inhibiting EMT and NSCLC metastasis via the miR-429/VASH2/ZEB1 axis.

Conclusions:

• KY216 effectively restrains NSCLC metastasis by modulating the VASH2 pathway and EMT.
• The study reveals a novel mechanism for MTA action involving VASH2 and miR-429, offering potential therapeutic targets for NSCLC.
• Understanding the structural basis of KY216-tubulin interaction provides insights for developing more effective anti-cancer agents.